Q-omics provides the consensus-scored COLEC10 profile across patient tissues and cancer cell-line models. COLEC10 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, COLEC10 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, COLEC10 RNA expression shows 12,874 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, THCA, and KIRP as cancer lineages where COLEC10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for COLEC10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes COLEC10 survival associations across molecular data types. COLEC10 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible COLEC10 RNA expression–survival associations across cancer types. High COLEC10 expression shows unfavorable associations in THYM and LGG, but favorable associations in KIRC, ACC, LIHC and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for COLEC10 RNA expression.
This table summarizes COLEC10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for COLEC10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. COLEC10 shows lower tumor expression in THCA, LIHC, LUAD, LUSC and KIRC and higher tumor expression in COAD. The THCA box plot shows higher COLEC10 RNA expression in normal versus tumor tissue (log2 FC = −1.514, t-test p < 0.001).
This table shows molecular features associated with COLEC10 in patient tissues and cancer cell lines. In patient samples, COLEC10 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, COLEC10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and OVARY.
